Search results

51 results

Sorted by Date . Sort by Relevance

  1. Developing and updating local formularies (MPG1)

    This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.

  2. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

    NICE has assessed the procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT

  3. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)

    This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.

  4. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

  5. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    NICE has assessed 3 viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems), to help the NHS decide whether to use these products

  6. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose

  7. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative

  8. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic

  9. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery

  10. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    Evidence-based recommendations on SeHCAT (tauroselcholic [75selenium] acid) for diagnosing bile acid malabsorption in people with IBS-D or Crohn’s disease

  11. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs

  12. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver